NCT05025098 (PALM) is a Phase 2 clinical trial of Standard therapy in AML, Adult, sponsored by University Hospital, Akershus.

Who is sponsoring NCT05025098?

NCT05025098 is sponsored by University Hospital, Akershus.

What drugs are being tested in NCT05025098?

Interventions in NCT05025098: Standard therapy, Precision therapy.

What condition does NCT05025098 study?

NCT05025098 studies AML, Adult, MDS.

Is NCT05025098 still recruiting?

NCT05025098 is currently recruiting now. Last updated 27 August 2021.

Last reviewed 2021-08-27 · How we verify

NCT05025098: PALM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Precision Therapy Versus Standard Therapy in AML and MDS in Elderly

Recruiting now Phase 2 Last updated 27 August 2021

What this trial tests

Phase 2 trial testing Standard therapy in AML, Adult in 36 participants. Currently enrolling.

Timeline

22 June 2021

Primary endpoint
10 June 2026

10 June 2027

Quick facts

Lead sponsor	University Hospital, Akershus
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	22 June 2021
Primary completion	10 June 2026
Estimated completion	10 June 2027
Sites	1 location across Norway

Drugs / interventions tested

Standard therapy — full drug profile →
Precision therapy — full drug profile →

Conditions studied

AML, Adult — all drugs for AML, Adult →
MDS — all drugs for MDS →

Sponsor

University Hospital, Akershus

Who can join

60 and older, any sex, with AML, Adult or MDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized clinical trial that randomizes between treatment principles. The study will investigate if precision therapy determined by a tumour board is better than standard treatment for acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) in elderly. The tumour board will decide the precision therapy based on identified genetic changes that can guide customized therapy. There are currently 40-50 targeted therapies approved for various cancers in Norway. The precision therapy will be given in addition to the standard treatment. The primary study objective will be to evaluate the cost-effectiveness of a precision therapy strategy compared with standard treatment. Other objectives will mesaure efficacy and satety of the treatment, and impact on life quality of the patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Standard therapy

Trials testing the same drug.

NCT07349836 — Application of mRNA Immunotherapy Technology in EB Virus Related Diseases · EARLY_PHASE1 · not yet recruiting
NCT07238985 — Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
NCT06297096 — Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease · Phase 3 · recruiting
NCT06925386 — The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment · Phase 2 · not yet recruiting
NCT06808256 — Effect of Acupuncture on Hemodynamics and Pain of Post Craniotomy Patients With Mechanical Ventilation · NA · completed

Other recruiting trials for AML, Adult

Currently open trials in the same condition.

NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
NCT07132684 — Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients · Phase 3 · recruiting
NCT06533761 — Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML · Phase 1 · recruiting
NCT07117422 — Venetoclax-Decitabine in Untreated Elderly/Unfit AML · NA · recruiting
NCT06313437 — Revumenib in Combination With 7+3 + Midostaurin in AML · Phase 1 · recruiting

Other University Hospital, Akershus trials

Trials by the same sponsor.

NCT06865027 — The Effect of Arterial Carbon Dioxide Levels on Cerebral Blood Flow and Cerebral Autoregulation in the Steep Trendelenbu · NA · enrolling by invitation
NCT06721754 — Diabetes Related Foot Ulcers with Negative Pressure Wound Therapy · NA · recruiting
NCT06731985 — The Follow-up After Shorter Tapes Study. Effectiveness and Safety of Shorter Trans-obturator Tapes. · recruiting
NCT06576752 — Management of Patients with Heart Failure At Home After Hospital Discharge · NA · recruiting
NCT06032715 — Brief Intervention for Sleep Medication Misuse Among Elderly · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05025098 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Akershus
Last refreshed: 27 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05025098.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing